Alameda, WI, United States of America

Chase Acton

USPTO Granted Patents = 2 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Chase Acton: Innovating COPD Management

Introduction

Chase Acton is a notable inventor based in Alameda, Wisconsin. With two patents to her name, she has made significant contributions to the field of healthcare technology, particularly in the management of chronic obstructive pulmonary disease (COPD).

Latest Patents

Chase's latest innovation is a groundbreaking system and method for providing real-time or near-real-time risk notifications for COPD exacerbation. This invention involves monitoring external medicament devices equipped with sensors that detect rescue and controller medication events. By analyzing medication use trends, the system can assess a patient's risk for exacerbation after each event, sending timely notifications to both the patient and their healthcare provider.

Career Highlights

Chase Acton is currently employed at Reciprocal Labs Corporation, where she continues to push the boundaries of medical technology. Her work focuses on enhancing patient care through innovative solutions that leverage real-time data for effective disease management.

Collaborations

Throughout her career, Chase has collaborated with esteemed colleagues such as Gregory F. Tracy and John David Van Sickle. These partnerships have fostered an environment of creativity and innovation, resulting in the development of advanced healthcare technologies.

Conclusion

Chase Acton's contributions to COPD management exemplify the power of innovation in improving patient outcomes. Her patents not only reflect her dedication to enhancing medical technology but also her commitment to addressing critical health challenges. As she continues her work at Reciprocal Labs Corporation, the impact of her inventions will likely resonate within the healthcare sector for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…